Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, R&D AND CSO

EVP, R&D and CSO

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to a...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-05	Premium	acquired	Premium	Premium	Premium	EVP, R&D AND CSO
2023-09-20	Premium	acquired	Premium	Premium	Premium	EVP, R&D AND CSO
2023-03-10	Premium	acquired	Premium	Premium	Premium	EVP, R&D and CSO
2021-08-12	Premium	bought	Premium	Premium	Premium	-
2021-08-12	Premium	acquired	Premium	Premium	Premium	-
2021-08-12	Premium	bought	Premium	Premium	Premium	-
2021-08-12	Premium	acquired	Premium	Premium	Premium	-

ELYM - Eliem Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for ELYM